医学
接种疫苗
内科学
临床终点
生活质量(医疗保健)
佐剂
观察研究
人口
随机对照试验
免疫学
环境卫生
护理部
作者
Andrew Bottomley,Channa Debruyne,Enriqueta Felip,Michael Millward,Luc Thiberville,Giannicola D’ Addario,Lisa Rome,Petr Zatloukal,Corneel Coens,Giuseppe Giaccone
标识
DOI:10.1016/j.ejca.2008.06.036
摘要
Aims This study reports the symptom and HRQOL results in which standard treatment was compared to standard therapy plus Bec2, an anti-idiotypic antibody that mimics GD3, a ganglioside antigen. Methods Five hundred and fifteen LD SCLC patients were randomised to receive five vaccinations of Bec2 (2.5 mg)/BCG vaccine arm (VA) or an observational arm (OA) administered over a 10-week period. Survival was the primary end-point; HRQOL was a secondary end-point, assessed using the EORTC QLQ-C30/LC 13. Results There was no improvement in survival or progression-free survival in the vaccination arm. At baseline patients in both arms demonstrated significantly impaired scores on the global QOL scale, when compared to a normative population. However, HRQOL and symptom scores between the two treatment arms were not statistically different at any time point. Conclusion We found no benefits to patient HRQOL by additional vaccination with Bec2/BCG to LD SCLC for patients who have been undergoing standard therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI